Egrifta Wr Kit
Product Images NDC 62064-381

Product Visual Gallery

This gallery contains 58 technical images submitted to the FDA as part of the official labeling for Egrifta Wr (NDC 62064-381). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Theratechnologies Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Egr00 0001 01)

Chemical structure of the active ingredient tesamorelin, shown as a detailed peptide sequence with amino acid abbreviations and a molecular formula fragment illustrating its composition.*

FDA Label Image

Figure 1 (Egr00 0001 02)

A set of two cumulative distribution plots labeled Study 1 and Study 2 showing percent of patients versus change in belly appearance distress. The x-axis ranges from -100 (worse) to 100 (better) and the y-axis shows cumulative patients from 0% to 100%. Two treatments are compared: a placebo (black line) and tesamorelin (gray line). Both studies illustrate shifts in patient-reported belly appearance distress changes for each treatment.*

FDA Label Image

Figure 2 (Egr00 0001 03)

Two line graphs titled Study 1 and Study 2 showing percent change from baseline in VAT over time from baseline to week 52. Each graph includes three groups represented by colored lines with different markers: blue diamonds for T-T, green squares for T-P, and red triangles for P-T, depicting varying trends in VAT percentage change across different study weeks.*

FDA Label Image

Thera Technologies (Egr00 0001 04)

FDA Label Image

Thera Patient Support (Egr00 0001 05)

FDA Label Image

Medication Box (Egr00 0001 06)

EGRIFTA WR (tesamorelin) medication box for injection, labeled as 11.6 mg per vial. The packaging indicates it is for subcutaneous use, single-patient use vial containing sterile lyophilized powder. The box includes a notice about new formulation, dose, mixing instructions, and storage, specifying one mixed vial provides daily doses for seven days. Labeler is Theratechnologies Inc., with product NDC 62064-381.*

FDA Label Image

Injection Box (Egr00 0001 07)

Box labeled 'INJECTION BOX' designed for EGRIFTA WR (tesamorelin) for injection 11.6 mg/vial by Theratechnologies Inc. The label notes this box is a kit (box 2 of 2) and includes mixing instructions, a bottle of bacteriostatic water, syringes with needles, alcohol swabs, and patient information but does not contain the EGRIFTA WR vial itself. It instructs storage at 20°C to 25°C and specifies the contents and usage information clearly on a white background with blue and red text.*

FDA Label Image

Figure A (Egr00 0001 08)

An instructional diagram titled 'Additional Supplies Required (not provided)' showing three items needed for use but not included: a red sharps disposal container, an adhesive bandage, and a gauze pad.*

FDA Label Image

Figure B (Egr00 0001 09)

Illustration of the EGRIFTA WR injection kit components including one vial of EGRIFTA WR 11.6 mg, one 30 mL bottle of bacteriostatic water for injection, one BD Plastipak 3 mL syringe with needle attached, and one alcohol swab. The items are organized into a Medication Box and an Injection Box.*

FDA Label Image

Figure C (Egr00 0001 10)

An instructional illustration labeled 'Figure C' showing a person washing hands under running water from a faucet with soap dispenser labeled 'Soap' visible nearby. The sink drain is also shown.*

FDA Label Image

Figure D (Egr00 0001 11)

An illustration showing a vial labeled 'EGRIFTA WR' intended to contain white to off-white powder. The graphic highlights the powder appearance inside the vial, which is part of the EGRIFTA WR (tesamorelin) KIT for subcutaneous use by Theratechnologies Inc.*

FDA Label Image

Figure E (Egr00 0001 12)

An illustration depicting two vials presumably included in the EGRIFTA WR kit. The smaller vial has a red cap, and the larger vial has a purple cap. Each vial label features an area indicating where to record the expiration date in a YYYY-MM format.*

FDA Label Image

Figure F (Egr00 0001 13)

An instructional illustration showing hands removing the red cap from a vial labeled with Tesamorelin (EGRIFTA WR) and a separate vial labeled "Bacteriostatic Water for Injection" with its pink flip cap being lifted. The image demonstrates how to access the contents of both vials, part of a subcutaneous injection kit by Theratechnologies Inc.*

FDA Label Image

Figure G (Egr00 0001 14)

An instructional illustration showing hands holding a vial labeled with the EGRIFTA WR logo, preparing it for use, alongside a separate vial labeled "Bacteriostatic Water for Injection." The image is likely part of directions for preparing the subcutaneous injection kit of tesamorelin by Theratechnologies Inc.*

FDA Label Image

Figure H (Egr00 0001 15)

An instructional illustration showing hands peeling open packaging containing a syringe prefilled with liquid. The syringe has measurement markings and the illustration is labeled Figure H, likely part of usage instructions for EGRIFTA WR, a tesamorelin subcutaneous injection kit by Theratechnologies Inc.*

FDA Label Image

Figure I (Egr00 0001 16)

An instructional illustration showing two hands preparing a syringe for injection. The right hand is holding the syringe with a needle cap being pulled off in the direction of a black arrow, indicating removal before use.*

FDA Label Image

Figure J (Egr00 0001 17)

An instructional illustration showing how to draw 1.5 mL of liquid into a syringe, highlighting the 1 1/2 mL measurement mark on the syringe barrel. The image includes a close-up view of the syringe scale with a red line indicating the fill level.*

FDA Label Image

Figure K (Egr00 0001 18)

An instructional diagram showing a hand inserting a syringe needle perpendicularly (at a 90-degree angle) into a vial labeled 'Bacteriostatic Water for Injection.' This image likely illustrates the proper technique for drawing medication from the vial.*

FDA Label Image

Figure L (Egr00 0001 19)

An instructional illustration depicting two hands preparing a syringe by drawing liquid from a vial, likely related to subcutaneous injection preparation for the EGRIFTA WR (tesamorelin) kit by Theratechnologies Inc.*

FDA Label Image

Figure M (Egr00 0001 20)

An instructional illustration showing a vial being held upside down while drawing liquid into a syringe. The syringe is marked with measurement increments, and the image includes a black arrow pointing upward, indicating the direction of liquid being drawn into the syringe. This instructional figure is related to preparing a subcutaneous injection.*

FDA Label Image

Figure N (Egr00 0001 21)

An instructional illustration showing a person drawing liquid from a vial into a syringe. The syringe measurement scale is highlighted, indicating that a tiny air bubble is normal and the liquid level should reach 1.5 mL (1 1/2 on the scale). The image aids in proper dose measurement for subcutaneous administration.*

FDA Label Image

Figure O (Egr00 0001 22)

An instructional illustration showing two hands preparing a syringe by drawing liquid from a vial. One hand holds the vial steady while the other pulls the syringe plunger to extract medication, indicated by an upward arrow. The vial label is partially visible but not legible.*

FDA Label Image

Figure P (Egr00 0001 23)

An instructional illustration shows a person using their fingers to remove air bubbles from a syringe. A close-up inset highlights the syringe filled with liquid, with an arrow pointing to the air bubbles near the top, indicating the proper step to expel air before injection. This is related to preparation of EGRIFTA WR (tesamorelin) kit for subcutaneous use.*

FDA Label Image

Figure Q (Egr00 0001 24)

An instructional illustration showing a hand holding a syringe with the plunger being drawn to 1.3 mL. A close-up inset highlights the top rim of the plunger aligned at the 1.3 mL mark on the syringe barrel. The image appears to demonstrate accurate measurement of a liquid dose in a syringe, relevant to subcutaneous injection preparation.*

FDA Label Image

Figure R (Egr00 0001 25)

An illustration labeled 'Injection Box' showing a vial of bacteriostatic water for injection. The vial has a gray cap and clear body with the text 'Bacteriostatic Water for Injection' visible on the label.*

FDA Label Image

Figure S (Egr00 0001 26)

Illustration showing two hands preparing an injection from a vial labeled EGRIFTA WR, with the syringe held at a 90-degree angle to the vial. The syringe is partially filled with liquid, demonstrating proper medication withdrawal technique from the vial.*

FDA Label Image

Figure T (Egr00 0001 27)

An instructional illustration depicting a hand drawing a liquid from a vial into a syringe and then withdrawing the syringe from the vial. The vial has a label with blue and purple markings. This diagram likely demonstrates part of the preparation process for subcutaneous administration of EGRIFTA WR (tesamorelin) kit.*

FDA Label Image

Figure U (Egr00 0001 28)

An instructional illustration showing a hand holding a syringe above a red sharps disposal container, demonstrating proper disposal of the syringe needle. This image is typically used in medication administration kits like EGRIFTA WR for safe injection practices.*

FDA Label Image

Figure V (Egr00 0001 29)

An instructional illustration showing a hand holding a small vial, rotating it gently side to side as indicated by circular arrows beneath, labeled as Figure V. This likely demonstrates proper handling or mixing technique for a medication vial.*

FDA Label Image

Figure W (Egr00 0001 30)

Illustration showing a vial of EGRIFTA WR (tesamorelin) with annotations pointing to a layer of foam and a clear solution inside the vial, indicating the solution is ready to be used.*

FDA Label Image

Figure X (Egr00 0001 31)

An illustrated diagram showing components of the EGRIFTA WR kit, including a medication vial labeled 'EGRIFTA WR' representing the mixed clear solution from weekly mixing, a BD SafetyGlide syringe with an orange cap needle, and two alcohol swab packets. The image is divided into labeled sections: Medication Box and Injection Box.*

FDA Label Image

Figure Y (Egr00 0001 32)

An illustration showing a pair of hands being washed with soap and water under a running faucet. A soap dispenser labeled 'Soap' is positioned beside the sink. The image likely demonstrates proper handwashing technique or hygiene.*

FDA Label Image

Figure Z (Egr00 0001 33)

An illustration showing two hands holding a small vial labeled with the Theratechnologies logo, depicting the handling or preparation of EGRIFTA WR (tesamorelin) kit for subcutaneous use.*

FDA Label Image

Figure Aa (Egr00 0001 34)

An instructional illustration showing two hands peeling open a foil pouch containing a pre-filled syringe with an orange liquid. The syringe is positioned vertically, and the image is labeled as Figure AA. This diagram likely demonstrates the opening or preparation step for subcutaneous injection.*

FDA Label Image

Figure Ab (Egr00 0001 35)

An instructional illustration showing hands preparing a syringe by pulling back a gray safety cap or cover on the needle. The orange and white syringe is held horizontally with a visible measurement scale on the barrel. A black arrow indicates the direction to rotate or remove the cap from the syringe.*

FDA Label Image

Figure Ac (Egr00 0001 36)

An instructional illustration showing a hand holding a syringe being uncapped by another hand pulling off an orange needle cover, demonstrating preparation for subcutaneous injection.*

FDA Label Image

Figure Ad (Egr00 0001 37)

An instructional illustration showing a hand holding a syringe at a 90-degree angle, extracting a liquid from a vial labeled EGRIFTA WR. Another hand holds the vial steady, with an orange needle cap visible to the side. The diagram is intended to demonstrate the correct method for drawing medication from the vial.*

FDA Label Image

Figure Ae (Egr00 0001 38)

An instructional illustration showing hands preparing a dosage from a vial with a syringe, likely representing the subcutaneous injection process for EGRIFTA WR (tesamorelin) kit supplied by Theratechnologies Inc.*

FDA Label Image

Figure Af (Egr00 0001 39)

An instructional illustration showing a person drawing liquid from a vial into a syringe, with a magnified view highlighting the syringe's measurement at 0.18 mL. The image visually demonstrates how to measure and withdraw a precise dose from the vial.*

FDA Label Image

Figure Ag (Egr00 0001 40)

An instructional illustration demonstrating how to draw medication from a vial using a syringe held at a 90-degree angle. The image shows one hand holding the vial upright while the other hand draws liquid into the syringe. A red safety cap is shown beside the vial.*

FDA Label Image

Figure Ah (Egr00 0001 41)

An instructional illustration showing a person tapping a syringe to remove air bubbles from the liquid inside. A close-up highlights air bubbles rising to the top of the syringe barrel, emphasizing the process of removing air before injection.*

FDA Label Image

Figure Ai (Egr00 0001 42)

An instructional illustration showing hands preparing a syringe for subcutaneous injection, indicating the process of drawing medication into the syringe. The syringe is marked with volume measurements, and the image demonstrates proper handling technique.*

FDA Label Image

Figure Aj (Egr00 0001 43)

An instructional illustration showing a hand holding a dosing syringe and adjusting liquid to the 16 (0.16 mL) mark, indicated by an enlarged magnified view of the syringe scale. The figure is labeled as 'Figure AJ'.*

FDA Label Image

Figure Ak (Egr00 0001 44)

Illustration showing hands removing an orange cap from a syringe. The image appears to be part of instructions related to the use of EGRIFTA WR (tesamorelin) kit for subcutaneous injection.*

FDA Label Image

Figure Al (Egr00 0001 45)

An illustration titled 'Medication Box' showing a vial labeled with the EGRIFTA WR logo and the phrase 'FOR RECONSTITUTION BY ADVANCE.' The vial contains a mixed and clear solution, indicating the medication's appearance after preparation.*

FDA Label Image

Figure Am (Egr00 0001 46)

An instructional illustration showing the abdomen of a person with a highlighted injection site area marked in green and a 2-inch diameter red circle in the center, indicating the recommended subcutaneous injection area for the drug EGRIFTA WR (tesamorelin).*

FDA Label Image

Figure An (Egr00 0001 47)

An instructional illustration showing a hand holding a small square alcohol pad wiping the skin around a navel area, likely to prepare the site for a subcutaneous injection.*

FDA Label Image

Figure Ao (Egr00 0001 48)

An instructional illustration showing two hands preparing a syringe by removing an orange safety cap from the needle, indicated by an arrow pointing right. This likely demonstrates a step in the subcutaneous injection process for the EGRIFTA WR (tesamorelin) kit.*

FDA Label Image

Figure Ap (Egr00 0001 49)

An illustration showing a hand pinching the skin on the abdomen, demonstrating a subcutaneous injection technique. The image is likely part of instructional content for subcutaneous administration associated with the product EGRIFTA WR (tesamorelin) kit by Theratechnologies Inc.*

FDA Label Image

Figure Aq (Egr00 0001 50)

An instructional illustration depicting a subcutaneous injection technique. The image shows a person pinching the skin and inserting a syringe at a 90-degree angle, demonstrating proper needle positioning for subcutaneous administration.*

FDA Label Image

Figure Ar (Egr00 0001 51)

An instructional illustration showing a hand holding a syringe inserted at a 90-degree angle into the skin, demonstrating the correct technique for subcutaneous injection for EGRIFTA WR (tesamorelin) kit by Theratechnologies Inc.*

FDA Label Image

Figure As (Egr00 0001 52)

An instructional illustration shows a hand holding a syringe perpendicular at a 90-degree angle to the skin surface, demonstrating the proper subcutaneous injection technique for the drug EGRIFTA WR (tesamorelin) kit by Theratechnologies Inc.*

FDA Label Image

Figure At (Egr00 0001 53)

An instructional diagram showing a hand holding a syringe at the skin surface, with an arrow pointing upward, illustrating the technique for subcutaneous injection, related to EGRIFTA WR (tesamorelin) kit administration.*

FDA Label Image

Figure Au (Egr00 0001 54)

An instructional diagram showing hands preparing a subcutaneous injection device. The first panel shows one hand holding a syringe-like device while the other hand removes a cap or cover. The second panel depicts the cap being lifted upwards with a labeled "CLICK" sound, indicating the step to remove the cover from the injection pen.*

FDA Label Image

Figure Av (Egr00 0001 55)

An instructional illustration showing a hand holding a syringe above a red disposal container with a white lid, demonstrating safe syringe disposal. The syringe is positioned to be inserted into the container's opening.*

FDA Label Image

Medication Box (Egr00 0001 56)

EGRIFTA WR tesamorelin injection kit containing 4 vials of 11.6 mg/vial sterile lyophilized powder for subcutaneous use. The medication box label includes dosage instructions, composition details, and manufacturer Theratechnologies Inc., Montreal, Quebec. The packaging highlights a new formulation, dose, mixing instructions, and storage information.*

FDA Label Image

Injection Box (no warning)

EGRIFTA WR (tesamorelin) injection box label for the 11.6 mg/vial subcutaneous kit by Theratechnologies Inc. The label details contents including bacteriostatic water, syringes, needles, and alcohol swabs. It specifies the box is for use with EGRIFTA WR and provides weekly mixing and daily injection instructions. Storage at 20°C to 25°C (68°F to 77°F) is indicated.*

FDA Label Image

Vial (Egr00 0001 60)

Label for EGRIFTA WR (tesamorelin) injection showing 11.6 mg per vial. The label indicates it is for subcutaneous use and single-patient use. It includes storage instructions (20°C to 25°C), states the product is sterile and prescription-only, and is manufactured by Theratechnologies Inc. The label also includes dosage information and space for lot and expiration dates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.